Diversity, Equity, Inclusion and Accessibility
I am part of a dedicated team of healthcare professionals, researchers, students and staff from different countries and various regions of the U.S. The culture of our Section is defined by the unique perspectives that we each bring with us. As both a large academic medical center and safety-net hospital serving the communities of Boston and its surroundings, our trainees engage in cutting edge research and gain real-world clinical experience by caring for local underserved populations. Our multilingual team is committed to promoting cultural competency, equity and inclusion in science, medicine and healthcare. We strive to maintain a workforce that is as diverse as the communities we serve, and aim to create a safe space for our members to learn, grow and succeed in their life goals. Acknowledging that we all have a role to play, I am dedicated to welcoming and celebrating individuals of all races, ethnicities, social backgrounds, religion, gender, sex, age, ability, sexual orientation, veteran status, and national origin.
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Fraser CS, Spetz JKE, Qin X, Presser A, Choiniere J, Li C, Yu S, Blevins F, Hata AN, Miller JW, Bradshaw GA, Kalocsay M, Sanchorawala V, Sarosiek S, Sarosiek KA. Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics. Nat Commun. 2022 Oct 02; 13(1):5789.View Related Profiles. PMID: 36184661; PMCID: PMC9527241; DOI: 10.1038/s41467-022-33461-z;
Hughes DM, Henshaw L, Blevins F, Edwards C, Lerner A, Sloan JM, Sanchorawala V. Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis. Clin Lymphoma Myeloma Leuk. 2022 Aug; 22(8):566-568.View Related Profiles. PMID: 35367193
Milrod CJ, Mann M, Blevins F, Hughes D, Patel P, Li KY, Lerner A, Sanchorawala V, Sloan JM. Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma. Crit Rev Oncol Hematol. 2022 Apr; 172:103644.View Related Profiles. PMID: 35227897; DOI: 10.1016/j.critrevonc.2022.103644;
Milrod CJ, Blevins F, Hughes D, Lerner A, Sarosiek S, Sanchorawala V, Sloan JM. Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs. Blood. 2021 05 27; 137(21):2987-2989.View Related Profiles. PMID: 33728443
Hughes D, Jhaveri R, Shah B, Blevins F, Rodriguez, A, Sarosiek S, Lerner A, Sloan JM, Sanchorawala V. Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis. Blood. 2020. View Publication
Hughes D, Blevins F, Shah B, Sarosiek S, Lerner A, Sloan JM. Blood. Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center. ASH Publications. 2019. View Publication
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.